Skip to main content

Affymetrix Subsidiary eBioscience Signs Distribution Deal With The Binding Site

NEW YORK (GenomeWeb) – Affymetrix today announced through its subsidiary, eBioscience, that the firm has entered into a multi-year distribution agreement with Birmingham, UK-based diagnostic tools supplier The Binding Site.

Under this agreement, The Binding Site has been granted the exclusive rights to distribute eBioscience clinical flow cytometry reagents in the clinical care market, including hospitals and reference labs.

"Our best-in-class full ASR and CE designated immunology and oncology antibody portfolio is a natural complement to the expertise of The Binding Site," Dara Grantham Wright, senior vice president of the eBioscience business at Affymetrix, said in a statement. "With this agreement we strengthen our emphasis on addressing the needs of the growing cancer diagnostics market."

The Binding Site began servicing US customers on Dec. 1 and will start to service customers outside the US on Feb. 15, 2015. The firm supplies reagents and instruments for in vitro diagnostics around the world.

Financial details of the agreement were not disclosed.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.